Some drugs are going generic this year and next

August 3, 2012 By Alexia Elejalde-Ruiz

Dozens of brand-name prescription drugs are losing their patent protection, allowing generic versions to enter the market and consumers to save 30 to 80 percent on those medications, said David Belian, director of media relations for the Generic Pharmaceutical Association.

Generic forms of drugs have the same active ingredients as their brand-name counterparts but are significantly cheaper because they don't invest in clinical trials or advertising, Belian said.

About 80 percent of prescriptions are filled with generic drugs, and they have a good track record, said Howard Schiff, executive director of the Maryland Pharmacists Association. But some generic drugs may not work as well as the original brands, so before making the switch consider consulting your doctor who can write a prescription specifying brand-name or generic, Schiff said.

These are the prescription drugs that have been or are expected to be released as generics in 2012 and 2013, according to , which manages pharmacy benefits for employer health plans.

2012: Symbyax (treatment-resistant depression); Geodon (schizophrenia, bipolar disorder); Lexapro (depression, anxiety); Seroquel (schizophrenia, bipolar disorder); Avandia (Type 2 diabetes); Avandamet (Type 2 diabetes); Avandaryl (Type 2 diabetes); Avapro (high blood pressure); Avalide (high blood pressure); Provigil (excessive sleepiness); Plavix (prevents blood clots); Viramune (HIV infection); Lescol/Lescol XL (high cholesterol); Tricor (high cholesterol); Clarinex/Clarinex D (, hives); Singulair (asthma and allergy symptoms); Actos (Type 2 diabetes); Xopenex (asthma, COPD); Revatio (); Diovan/Diovan HCT (high blood pressure); Detrol (); Lidoderm (pain from post-herpetic neuralgia); Atacand/Atacand HCT (); Evoxac (Sjogren's syndrome); Maxalt/Maxalt MLT (migraines); Actoplus Met (Type 2 diabetes).

2013: Opana ER (pain); Zometa (bone complications from cancer); Valcyte (viral infections); Zomig (migraines); Fosamax Plus D (osteoporosis); Rilutek (amyotrophic lateral sclerosis); Temodar (glioblastoma multiforme); Cerezyme (Gaucher disease); Niaspan (high cholesterol); Advicor (); AcipHex (GERD); Vivelle-DOT (menopausal symptoms); Cymbalta (depression, anxiety, nerve/musculoskeletal pain, fibromyalgia).

Explore further: Americans turn to generic medications in 2010: report

Related Stories

Americans turn to generic medications in 2010: report

April 22, 2011
(Medical Xpress) -- In a new report released by the IMS Institute for Healthcare Informatics, the results show that over 78% of the almost four billion prescriptions written in the U.S. in 2010 were for generic drugs. The ...

Global spending on drugs to slow through 2016

July 12, 2012
(AP) — Growth in global spending on medications will slow markedly over the next four years due to a large number of new low-cost generic drugs coming to pharmacies in the U.S. and other developed countries, along with ...

Drug prices to plummet in wave of expiring patents

July 25, 2011
The cost of prescription medicines used by millions of people every day is about to plummet. The next 14 months will bring generic versions of seven of the world's 20 best-selling drugs, including the top two: cholesterol ...

FDA approves first generic versions of Zyprexa

October 24, 2011
(AP) -- Federal health officials on Monday approved the first generic versions of the blockbuster drug Zyprexa, an expensive treatment for schizophrenia and bipolar mood disorder.

Generic boniva approved for osteoporosis

March 19, 2012
(HealthDay) -- The first generic versions of the once-monthly osteoporosis drug Boniva (ibandronate) have been approved by the U.S. Food and Drug Administration.

Recommended for you

Drug for spinal muscular atrophy prompts ethical dilemmas, bioethicists say

December 11, 2017
When the Food and Drug Administration approved the first drug for people with spinal muscular atrophy a year ago, clinicians finally had hope for improving the lives of patients with the rare debilitating muscular disease. ...

FDA's program to speed up drug approval shaved nearly a year off the process

December 7, 2017
Speeding the pace at which potentially lifesaving drugs are brought to market was a rallying cry for Donald Trump as a candidate, and is a stated priority of his Food and Drug Administration commissioner, Dr. Scott Gottlieb. ...

Dangers of commonly prescribed painkillers highlighted in study

December 6, 2017
Commonly prescribed painkillers need to be given for shorter periods of time to reduce the risk of obesity and sleep deprivation, a new study has revealed.

Viagra goes generic: Pfizer to launch own little white pill

December 6, 2017
The little blue pill that's helped millions of men in the bedroom is turning white. Drugmaker Pfizer is launching its own cheaper generic version of Viagra rather than lose most sales when the impotence pill gets its first ...

Surgery-related opioid doses can drop dramatically without affecting patients' pain

December 6, 2017
Some surgeons might be able to prescribe a third of opioid painkiller pills that they currently give patients, and not affect their level of post-surgery pain control, a new study suggests.

Four-fold jump in deaths in opioid-driven hospitalizations

December 4, 2017
People who end up in the hospital due to an opioid-related condition are four times more likely to die now than they were in 2000, according to research led by Harvard Medical School and published in the December issue of ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Osiris1
not rated yet Aug 12, 2012
Fosamax will disappear in the wave of lawsuits against its manufacturer. No generic manufacturer in his right mind would ever touch that poison.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.